KORU Medical Systems, Inc. Q2 2026 Earnings Call Summary - MobyStrategic Execution and Performance AttributionOur analysts just identified a stock with the potential to be the next Nvidia. Delivered 18% revenue growth in Q2, reaching positive net income for the first time since 2019, validating the company's path toward profitable scale. International revenue surged 59% driven by established market momentum and distributor-led conversions to prefilled syringe (PFS) formats in Europe. Expects near-term international growth to moderate in the second half of 2026, with more meaningful revenue contributions from new geographies shifting into 2027. Anticipates positive adjusted EBITDA for the full year 2026 while continuing strategic investments in R&D and sales and marketing.